CIK 0001649094
- Large accelerated filer
Vaxcyte, Inc.
Sign in to watch- Ticker
- PCVX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464233385
- Phone
- +1 650-837-0111
- Business address
- 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070
- Former names
- SutroVax, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,185,988
- in 8 filings, $4.8M under 10b5-1 plans
Net −$5,185,988. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 88 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-12-30 | PICKERING GRANT Chief Executive Officer | Exercise or conversion | +15,158 | $2.03 | $31K | 374,476 |
| 2022-12-30 | PICKERING GRANT Chief Executive Officer | Grant or award · Stock Option (right to buy) | +108,250 | 108,250 | ||
| 2022-12-30 | PICKERING GRANT Chief Executive Officer | Exercise or conversion · Stock Option (right to buy) | −15,158 | 302,227 | ||
| 2022-12-28 | Dhaliwal Harpreet S. SVP Cml Mfg & Supply Chain | Exercise or conversion | +3,990 | $25.06 | $100K | 21,808 |
| 2022-12-28 | Dhaliwal Harpreet S. SVP Cml Mfg & Supply Chain | Returned to the company · Stock Option (Right to Buy) | +3,990 | 96,010 | ||
| 2022-12-23 | Wassil Jim Chief Operating Officer | Exercise or conversion | +105,371 | $2.42 | $255K | 147,715 |
| 2022-12-23 | Wassil Jim Chief Operating Officer | Exercise or conversion · Stock Option (right to buy) | −105,371 | 116,555 | ||
| 2022-12-12 | Lukatch Heath Director | Exercise or conversion | +335 | $16.00 | $5K | 3,460 |
| 2022-12-12 | Lukatch Heath Director | Sale | −16 | $42.37 | $678 | 3,444 |
| 2022-12-12 | Lukatch Heath Director | Sale | −319 | $44.01 | $14K | 3,125 |
| 2022-12-12 | Lukatch Heath Director | Exercise or conversion · Stock Option (right to buy) | −335 | 28,315 | ||
| 2022-11-10 | Lukatch Heath Director | Exercise or conversion | +4,335 | $16.00 | $69K | 7,460 |
| 2022-11-10 | Lukatch Heath Director | Sale | −335 | $44.74 | $15K | 7,125 |
| 2022-11-10 | Lukatch Heath Director | Sale | −4,000 | $46.25 | $185K | 3,125 |
| 2022-11-10 | Lukatch Heath Director | Exercise or conversion · Stock Option (right to buy) | −4,335 | 28,650 | ||
| 2022-10-26 | Fairman Jeff VP, Research | Sale | −10,000 | $40.00 | $400K | 286,227 |
| 2022-10-26 | Lukatch Heath Director | Exercise or conversion | +4,000 | $16.00 | $64K | 7,125 |
| 2022-10-26 | Lukatch Heath Director | Sale | −4,000 | $38.25 | $153K | 3,125 |
| 2022-10-26 | Lukatch Heath Director | Returned to the company · Stock Option (right to buy) | −4,000 | 32,985 | ||
| 2022-10-24 | Lukatch Heath Director | Exercise or conversion | +3,015 | $16.00 | $48K | 6,140 |
Page 43 of 51 · 1,004 trades